These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 183135)

  • 41. Inhibition of cyclic AMP phosphodiesterase by flavonoids.
    Nikaido T; Ohmoto T; Sankawa U; Hamanaka T; Totsuka K
    Planta Med; 1982 Nov; 46(3):162-6. PubMed ID: 6294714
    [No Abstract]   [Full Text] [Related]  

  • 42. Selective inhibition of cyclic nucleotide phosphodiesterases by analogues of 1-methyl-3-isobutylxanthine.
    Kramer GL; Garst JE; Mitchel SS; Wells JN
    Biochemistry; 1977 Jul; 16(15):3316-21. PubMed ID: 196632
    [No Abstract]   [Full Text] [Related]  

  • 43. Cardiotonic agents. 3. A topographical model of the cardiac cAMP phosphodiesterase receptor.
    Erhardt PW; Hagedorn AA; Sabio M
    Mol Pharmacol; 1988 Jan; 33(1):1-13. PubMed ID: 2826995
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A heat-stable inhibitor protein for bovine brain cyclic nucleotide phosphodiesterase from Escherichia coli.
    Iwasa Y; Yonemitsu K; Matsui K; Fukunaga K; Miyamoto E
    FEBS Lett; 1981 Jun; 128(2):311-4. PubMed ID: 6266875
    [No Abstract]   [Full Text] [Related]  

  • 45. Studies on the inhibition by beta adrenergic receptor agonists of cyclic AMP phosphodiesterase activity of rat heart.
    Ain-Shoka AA; Buckner CK
    Arch Int Pharmacodyn Ther; 1978 Apr; 232(2):269-78. PubMed ID: 28097
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide.
    Jones GH; Venuti MC; Alvarez R; Bruno JJ; Berks AH; Prince A
    J Med Chem; 1987 Feb; 30(2):295-303. PubMed ID: 3027338
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure/activity studies of flavonoids as inhibitors of cyclic AMP phosphodiesterase and relationship to quantum chemical indices.
    Ferrell JE; Chang Sing PD; Loew G; King R; Mansour JM; Mansour TE
    Mol Pharmacol; 1979 Sep; 16(2):556-68. PubMed ID: 229402
    [No Abstract]   [Full Text] [Related]  

  • 48. Protein inhibitor of cyclic adenosine 3':5'-monophosphate phosphodiesterase in retina.
    Dumler IL; Etingof RN
    Biochim Biophys Acta; 1976 Apr; 429(2):474-8. PubMed ID: 177072
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 50. Antispasmodic action of 1-diethylaminoethyl-3-(p-methoxybenzyl)-2-quinoxalone (P 201-1) and its inhibitory effect on cyclic 3',5'-nucleotide phosphodiesterase (PDE) activity.
    Hayashi S; Ozawa H
    Chem Pharm Bull (Tokyo); 1975 Apr; 23(4):810-6. PubMed ID: 171085
    [No Abstract]   [Full Text] [Related]  

  • 51. Effects of cyclic AMP pulses on adenylate cyclase and the phosphodiesterase inhibitor of D. discoideum.
    Klein C; Darmon M
    Nature; 1977 Jul; 268(5615):76-8. PubMed ID: 196203
    [No Abstract]   [Full Text] [Related]  

  • 52. Cyclic AMP phosphodiesterase from human heart and drug action.
    Tanaka T; Masuoka H; Ito M; Nakano T; Naka M; Hidaka H
    Adv Second Messenger Phosphoprotein Res; 1992; 25():373-81. PubMed ID: 1313268
    [No Abstract]   [Full Text] [Related]  

  • 53. Influence of tricyclic antidepressants on the adenylate cyclase-phosphodiesterase system in the rat cortex.
    Palmer GC
    Neuropharmacology; 1976 Jan; 15(1):1-7. PubMed ID: 176608
    [No Abstract]   [Full Text] [Related]  

  • 54. [Effect of antioxidants of the 3-hydroxypyridine class on cyclic 3', 5'-adenosine monophosphate phosphodiesterase activity].
    Smirnov LD; Malykhina LS; Lazarevich VG; Fedorov NA
    Biull Eksp Biol Med; 1983 Sep; 96(9):40-2. PubMed ID: 6311309
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4).
    O'Donnell JM; Zhang HT
    Trends Pharmacol Sci; 2004 Mar; 25(3):158-63. PubMed ID: 15019272
    [No Abstract]   [Full Text] [Related]  

  • 56. Effect of prostaglandin E2 on two different preparations of cyclic 3',5'-nucleotide phosphodiesterase.
    Egg D; Gantner G
    Pharmacol Res Commun; 1978 Jul; 10(7):609-17. PubMed ID: 213791
    [No Abstract]   [Full Text] [Related]  

  • 57. Pharmacological inhibition of calmodulin-sensitive phosphodiesterases.
    Ilien B; Ruckstuhl M; Landry Y
    J Pharmacol; 1982; 13(2):307-16. PubMed ID: 6285085
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors.
    Devillers I; Pevet I; Jacobelli H; Durand C; Fasquelle V; Puaud J; Gaudillière B; Idrissi M; Moreau F; Wrigglesworth R
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3303-6. PubMed ID: 15149695
    [No Abstract]   [Full Text] [Related]  

  • 59. Adenosine cyclic 3',5',-monophosphate phosphodiesterasr inhibitors. 2.3-Substituted 5,7-dialkylpyrazolo [1,5-a]pyrimidines.
    Novinson T; Miller JP; Scholten M; Robins RK; Simon LN; O'Brien DE; Meyer RB
    J Med Chem; 1975 May; 18(5):460-4. PubMed ID: 168380
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interaction of four methylxanthine compounds and norepinephrine on cardiac phosphorylase activation and cardiac contractility.
    McNeill JH; Brenner MJ; Muschek LD
    Recent Adv Stud Cardiac Struct Metab; 1973; 3():261-73. PubMed ID: 4377599
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.